APL-130277 Approval Status
APL-130277 (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine in development for the on-demand management of OFF episodes associated with Parkinson’s disease (PD).
Development Status and FDA Approval Process for APL-130277
|Jan 30, 2019||Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)|
|Jun 12, 2018||Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)|